Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Novo Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
Novo Ventures

Novo Ventures

Operating

Danish-based Novo A/S, a private holding company, is fully owned by the Novo Nordisk Foundation.

Location
Copenhagen, Capital Region of Denmark, DK
Founded
1999
Firm
Compare
Portfolio
Employees

Investments

Inbrace
Inbrace

Total Raised

$217.6M

Rounds

7

Series D$102MSeptember 2021
Unchained Labs
Unchained Labs

Total Raised

$285M

Rounds

6

Series D$17MMarch 2018
Series C$13MJune 2017
Series B$25MFebruary 2016
Series A$25MFebruary 2015
ViewPoint Therapeutics
ViewPoint Therapeutics
Acquired

Total Raised

$39M

Rounds

2

Series B$35MMarch 2018
Minerva Surgical
Minerva Surgical
Public

Total Raised

$173.9M

Rounds

9

Series Unknown$16.7MDecember 2016
Arch Oncology
Arch Oncology

Total Raised

$250.4M

Rounds

5

Series A$86MAugust 2016
PanOptica
PanOptica
Acquired

Total Raised

$109.9M

Rounds

5

Series B$23.9MMay 2016
Series B$45MApril 2014
Cardeas Pharma
Cardeas Pharma

Total Raised

$80M

Rounds

3

Series B$37.5MApril 2015
Series A$8.5MJune 2012
Thesan Pharmaceuticals
Thesan Pharmaceuticals

Total Raised

$65M

Rounds

3

Series B$49MFebruary 2014
Series A$16MOctober 2012
Nevro
Nevro
Public

Total Raised

$555.8M

Rounds

8

Series C$48MMarch 2013
Imagen Biotech
Imagen Biotech

Total Raised

$40M

Rounds

1

Series A$40MOctober 2011
NeuroTherapeutics Pharma
NeuroTherapeutics Pharma
Public

Total Raised

$60.7M

Rounds

4

Series B$43MMay 2010
Tarsa Therapeutics
Tarsa Therapeutics
Acquired

Total Raised

$124.3M

Rounds

9

Series A$24MJanuary 2010
CymaBay Therapeutics
CymaBay Therapeutics
Acquired

Total Raised

$710.2M

Rounds

16

Series E$8.6MNovember 2009
Series D$32MApril 2007
MediQuest Therapeutics
MediQuest Therapeutics

Total Raised

$44.8M

Rounds

5

Series B$23MJune 2009